DESCRIPTION

• Notes: The AAV-DJ viruses are covered under several patents, including U.S. Patent Nos. 7,588,772, 8,067,014, 8,574,583, and 8,906,387, as well as corresponding foreign patents applications and patent rights. AAV-DJ is used under a license agreement. Troubleshooting Guide: Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com. Biosafety: Recombinant AAV is inherently replication-deficient and not known to cause any human diseases. Additionally, following transduction, AAV vectors exist episomally and do not integrate into or disrupt the host cell's genome. AAV requires the use of a Biosafety Level 1 facility. BPS Bioscience recommends following all local, federal, state, and institutional regulations and using all appropriate safety precautions
• Species: AAV-DJ
• Shiptemp: -80°C (dry ice)
• Warnings: Avoid freeze/thaw cycles
• Category: CART/AAV
• Background: Adeno-Associated Virus-DJ (AAV-DJ) is a synthetic serotype made from eight different wild-type AAV serotypes (AAV2, 4, 5, 8, 9, avian, bovine, and goat AAV) using DNA shuffling. These modifications allow the AAV-DJ serotype to exhibit improved transduction efficiency in vitro and in vivo and infect a broader range of cell types compared to the wild-type serotypes. CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.
• Description: The AAV-DJ Anti-CD19 CAR (CD19 ScFv-CD8-4-1BB-CD3ζ) is an AAV-DJ encoding the ScFv portion of anti-CD19 (clone FMC63) linked to the 2nd generation CAR (Chimeric Antigen Receptor) containing the CD8 hinge, 4-1BB and CD3ζ signaling domains, under the control of a EF1α promoter (Figure 1)._x000D_ _x000D_ Figure 1. Schematic representation of AAV-DJ Anti-CD19 CAR (CD19 ScFv-CD8-4-1BB-CD3ζ). The diagram indicates the components of the anti-CD19 CAR (ScFv-CD8-4-1BB-CD3ζ).
• Formulation: AAV was produced in HEK293 cells and is supplied in PBS-MK (PBS Magnesium-Potassium) buffer containing 0.01% Pluronic F68. Viral particles can be packaged in custom formulations by special request, for an additional fee.
• Supplied As: Two vials (50 µl x 2) of AAV at a titer ?1 x 1012 vector genomes/ml. The titer is determined by qPCR and varies with each lot; the exact value will be provided with each shipment
• Unspsc Code: 41106621
• Unspsc Name: Virus mediated expression vectors or kits
• Applications: Positive control for anti-CD19 CAR evaluation in T cells. Transduction optimization experiments. Generate anti-CD19 CAR-T cells (for research use only, not for therapeutic purposes).
• Product Type: AAV virus
• Purification: Purity of the AAV particles was confirmed to be greater than 90% by staining with One-Step Lumitein™ UV Protein Gel Stain (Biotium #21005-1L). The purity will vary with each lot; the exact value will be provided with each shipment.
• Biosafety Level: BSL-1
• Related Products: 79853, 78601, 78775
• Storage Stability: AAV is shipped with dry ice. For long-term storage, it is recommended to store AAV at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle
• Scientific Category: Immunotherapy Target
• Signed License Required: No